» Articles » PMID: 19306136

Penetration of Moxifloxacin into Rat Mandibular Bone and Soft Tissue

Overview
Specialty Dentistry
Date 2009 Mar 24
PMID 19306136
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Based on its in vitro activity and spectrum of activity, the new 8-methoxyquinolone antibiotic moxifloxacin (MXF) seems suited for the antibiotic therapy of odontogenic infections. Penetration into the relevant tissue is another prerequisite for clinical efficacy. For this reason, the levels of MXF in plasma, soft tissue, and mandibular bone were determined in an animal model with Wistar rats.

Material And Methods: Samples of 49 rats were analyzed. Tissue samples were homogenized and proteins were precipitated. The pharmacokinetic evaluation was conducted based on non-compartmental analysis.

Results: The concentration-time courses of tissues show a more plateau-shaped curve compared to plasma. Calculated AUC (area under the curve) ratios tissue:plasma were M. masseter:plasma = 2.64 and mandibles:plasma = 1.13.

Conclusions: Administration of antibiotics is considered an important part of therapy during and/or after surgical procedures in the maxillofacial area. Because of the good penetration into bone and muscle tissues demonstrated in Wistar rats, MXF might be an option for clinical application in this indication.

Citing Articles

Clinical and Microbiological Efficacy of Adjunctive Systemic Quinolones to Mechanical Therapy in Periodontitis: A Systematic Review of the Literature.

Ardila C, Bedoya-Garcia J Int J Dent. 2022; 2022:4334269.

PMID: 35637653 PMC: 9148240. DOI: 10.1155/2022/4334269.


A multilevel analysis of a randomized clinical trial comparing adjunctive moxifloxacin versus amoxicillin/metronidazole for the treatment of aggressive periodontitis.

Ardila C, Bedoya-Garcia J Dent Res J (Isfahan). 2021; 18:44.

PMID: 34429864 PMC: 8351943.


Is the penetration of clindamycin into the masseter muscle really enough to treat odontogenic infections?.

Faggion P, Isoton G, Possa E, Tasso L Clin Oral Investig. 2020; 25(5):3257-3266.

PMID: 33128135 DOI: 10.1007/s00784-020-03656-z.


Moxifloxacin versus Clindamycin/Ceftriaxone in the management of odontogenic maxillofacial infectious processes: A preliminary, intrahospital, controlled clinical trial.

Gomez-Arambula H, Hidalgo-Hurtado A, Rodriguez-Flores R, Gonzalez-Amaro A, Garrocho-Rangel A, Pozos-Guillen A J Clin Exp Dent. 2015; 7(5):e634-9.

PMID: 26644841 PMC: 4663067. DOI: 10.4317/jced.52627.


Systemic moxifloxacin vs amoxicillin/metronidazole adjunct to non-surgical treatment in generalized aggressive periodontitis.

Guzeldemir-Akcakanat E, Gurgan C Med Oral Patol Oral Cir Bucal. 2015; 20(4):e441-9.

PMID: 26034931 PMC: 4523257. DOI: 10.4317/medoral.20552.